Supplementary Material for: Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration: XTEND at 3 Years

Supplementary Material for: Aflibercept 2 mg for Neovascular Age-Related Macular Degeneration: XTEND at 3 Years

Introduction: Long-term, global, data evaluating intravitreal aflibercept (IVT-AFL) 2 mg for treatment of neovascular age-related macular degeneration (nAMD) in real-world practice are needed. This study investigated the long-term, real-world effectiveness and safety of IVT-AFL 2 mg in patients with...

Full description

Saved in:
Bibliographic Details
Main Author: figshare admin karger (2628495) (author)
Other Authors: Korobelnik J.-F. (8436039) (author), Chaudhary V. (11640451) (author), Mitchell P. (3182421) (author), Kang S.W. (4490593) (author), Allmeier H. (21026864) (author), Lee J. (2862626) (author), Zhang X. (3333504) (author), Machewitz T. (21026867) (author), Bailey C. (20386236) (author)
Published: 2025
Subjects:
Medicine
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items